Euroapi (EAPI) Panoramica del titolo
Euroapi S.A. sviluppa, produce, commercializza e distribuisce ingredienti farmaceutici attivi e intermedi utilizzati nella formulazione di farmaci per uso umano e veterinario. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
EAPI Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Euroapi S.A.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | €1.50 |
| Massimo di 52 settimane | €3.57 |
| Minimo di 52 settimane | €1.22 |
| Beta | 0.96 |
| Variazione di 1 mese | 17.37% |
| Variazione a 3 mesi | -29.78% |
| Variazione di 1 anno | -52.08% |
| Variazione a 3 anni | -85.27% |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | -88.90% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • May 10
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Euroapi's analyst price target has shifted lower from about €3.08 to €2.00, with analysts pointing to Deutsche Bank's recent cut in its target to €1, along with updated views on revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts may see the lower price target range, now clustering around €1 to €2, as setting a more conservative bar for execution, which can reduce the risk of further valuation resets if expectations are now better aligned with current fundamentals.
Aggiornamento della narrazione • Apr 22
EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings
Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.
Aggiornamento della narrazione • Apr 08
EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds
Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.Aggiornamento della narrazione • Mar 25
EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality
Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.Recent updates
Aggiornamento della narrazione • May 10
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Euroapi's analyst price target has shifted lower from about €3.08 to €2.00, with analysts pointing to Deutsche Bank's recent cut in its target to €1, along with updated views on revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts may see the lower price target range, now clustering around €1 to €2, as setting a more conservative bar for execution, which can reduce the risk of further valuation resets if expectations are now better aligned with current fundamentals.Aggiornamento della narrazione • Apr 22
EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings
Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.Aggiornamento della narrazione • Apr 08
EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds
Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.Aggiornamento della narrazione • Mar 25
EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality
Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.Aggiornamento della narrazione • Mar 10
EAPI: Weaker 2025 Guidance Will Pressure Margins And Future Earnings Quality
Analysts have cut their Euroapi price target from €2 to €1, reflecting updated assumptions that now factor in lower revenue growth expectations, much slimmer profit margins, and a significantly higher future P/E multiple. Analyst Commentary Recent price target revisions point to a cautious stance from bearish analysts, who appear focused on execution risks and the implications for Euroapi's valuation.Aggiornamento della narrazione • Feb 24
EAPI: Lower 2025 Guidance And Reduced Multiple Will Shape Return Profile
Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing updated assumptions on modest revenue growth, slightly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent research points to a more cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.Aggiornamento della narrazione • Feb 09
EAPI: Lower 2025 Outlook And Cautious Stance Will Shape Return Profile
Analysts have lowered their price target on Euroapi from €2.50 to €2, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that collectively suggest a more cautious valuation stance. Analyst Commentary Bearish analysts have recently cut their price target on Euroapi from €2.50 to €2.Aggiornamento della narrazione • Jan 25
EAPI: Execution Risks And Lower Outlook Will Shape Future Return Profile
Narrative update Analysts have trimmed their price target on Euroapi by €0.50 to €2.00, citing updated assumptions on revenue growth, profit margins and forward P/E that keep their stance cautious on the shares. Analyst Commentary Recent research has reinforced a cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.00.Aggiornamento della narrazione • Jan 10
EAPI: Lower Profitability Assumptions And New Partnership Will Shape Future Returns
Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing softer assumptions around revenue growth, profit margins and a higher future P/E multiple as the key drivers of the reset. Analyst Commentary Bearish analysts are signalling a cautious stance on Euroapi by aligning around a lower price target of €2, narrowed from €2.50.Aggiornamento della narrazione • Dec 19
EAPI: Higher Discount Rate Will Outweigh Benefits From New Corticosteroid Partnership
Analysts have slightly reduced their Euroapi price target, reflecting a modest reassessment of fair value. This adjustment accounts for a higher discount rate, even as long term profit margin assumptions edge up and revenue declines appear marginally less severe.Articolo di analisi • Dec 18
Calculating The Intrinsic Value Of Euroapi S.A. (EPA:EAPI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €2.68 Euroapi's €2.40 share...Articolo di analisi • Dec 18
Euroapi S.A. (EPA:EAPI) Not Doing Enough For Some Investors As Its Shares Slump 26%
Euroapi S.A. ( EPA:EAPI ) shareholders that were waiting for something to happen have been dealt a blow with a 26...Articolo di analisi • Oct 03
Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Articolo di analisi • Aug 02
Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates
It's been a mediocre week for Euroapi S.A. ( EPA:EAPI ) shareholders, with the stock dropping 12% to €2.79 in the week...
Nuova narrazione • Mar 31
Capacity Expansion And Efficiency Improvements Will Shape Future Success
Euroapi focuses on high-margin differentiated APIs and CDMO services to boost sustainable revenue and profit margins through strategic project expansions.Articolo di analisi • Mar 06
Analyst Estimates: Here's What Brokers Think Of Euroapi S.A. (EPA:EAPI) After Its Annual Report
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...Articolo di analisi • Oct 04
Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price
Key Insights The projected fair value for Euroapi is €2.62 based on 2 Stage Free Cash Flow to Equity Current share...Articolo di analisi • Jul 29
There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise
Euroapi S.A. ( EPA:EAPI ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...Articolo di analisi • May 24
Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Those holding Euroapi S.A. ( EPA:EAPI ) shares would be relieved that the share price has rebounded 29% in the last...Articolo di analisi • Apr 10
Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Mar 03
Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding
The Euroapi S.A. ( EPA:EAPI ) share price has fared very poorly over the last month, falling by a substantial 31%. For...Articolo di analisi • Mar 02
Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a major selloff in Euroapi S.A. ( EPA:EAPI ) shares in the week since it released its yearly report, with...Articolo di analisi • Dec 21
A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €5.03 With €5.47 share price...Articolo di analisi • Aug 04
Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...Articolo di analisi • Aug 02
Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €24.50 Euroapi is estimated to...Articolo di analisi • Jun 16
Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity
When close to half the companies operating in the Pharmaceuticals industry in France have price-to-sales ratios (or...Articolo di analisi • Jan 25
An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued
Key Insights Euroapi's estimated fair value is €21.9 based on 2 Stage Free Cash Flow to Equity Current share price of...Rendimenti per gli azionisti
| EAPI | FR Pharmaceuticals | FR Mercato | |
|---|---|---|---|
| 7D | 4.6% | 3.4% | 1.8% |
| 1Y | -52.1% | -11.4% | 0.4% |
Ritorno vs Industria: EAPI ha avuto una performance inferiore rispetto al French Pharmaceuticals che ha registrato un rendimento -11.4 % nell'ultimo anno.
Rendimento vs Mercato: EAPI ha avuto una performance inferiore al mercato French che ha registrato un rendimento 0.4 % nell'ultimo anno.
Volatilità dei prezzi
| EAPI volatility | |
|---|---|
| EAPI Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in FR Market | 10.7% |
| 10% least volatile stocks in FR Market | 3.0% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di EAPI è stato volatile rispetto al mercato French.
Volatilità nel tempo: La volatilità settimanale ( 9% ) di EAPI è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni French.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2020 | 2,961 | David Seignolle | www.euroapi.com/en |
Euroapi S.A. sviluppa, produce, commercializza e distribuisce ingredienti farmaceutici attivi e intermedi utilizzati nella formulazione di farmaci per uso umano e veterinario. L'azienda fornisce un'organizzazione di sviluppo e produzione a contratto per diverse classi di tidi che utilizza la chimica in fase solida, l'ingegneria delle particelle, la fermentazione microbica, la sintesi di piccole molecole, prostaglandine, steroidi e ormoni, oppiacei e sostanze controllate, nonché lipidi. Offre i propri prodotti a case farmaceutiche, produttori di farmaci generici, produttori di prodotti per la salute degli animali, aziende di prodotti per la salute dei consumatori, nutrizione e cosmetici, aziende biotecnologiche e società di distribuzione, nonché organizzazioni di sviluppo e produzione a contratto.
Euroapi S.A. Riepilogo dei fondamenti
| EAPI statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | €142.78m |
| Utili (TTM) | -€211.20m |
| Ricavi(TTM) | €852.60m |
0.2x
Rapporto P/S-0.7x
Rapporto P/EEAPI è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| EAPI Conto economico (TTM) | |
|---|---|
| Ricavi | €852.60m |
| Costo del fatturato | €707.70m |
| Profitto lordo | €144.90m |
| Altre spese | €356.10m |
| Utili | -€211.20m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
Jul 28, 2026
| Utile per azione (EPS) | -2.22 |
| Margine lordo | 17.00% |
| Margine di profitto netto | -24.77% |
| Rapporto debito/patrimonio netto | 5.8% |
Come si è comportato EAPI nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/25 05:46 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Euroapi S.A. è coperta da 11 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Justin Steven Smith | Bernstein |
| Patrick Andrew Wood | BofA Global Research |
| Fynn Scherzler | Deutsche Bank |